VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy (ViroMed Co Ltd)

(Source: ViroMed Co Ltd) First Pivotal Gene Therapy Trial to Target Underlying Cause of Diabetic Peripheral Neuropathy June 27, 2016 - Atlanta, GA- VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, Korea (KOSDAQ:084990), today announced the first patient was dosed in the recently initiated Phase 3 clinical study evaluating VM202, a proprietary DNA based biopharmaceutical, in patients with painful diabetic peripheral neuropathy (DPN). This is the first pivotal gene therapy trial specifically targeting the most common cause of severe neuropathy, and follows the successful completion of a Phase 2 trial conducted at Northwestern University and multinational sites in the...